
selected that is capable of maintaining in solution not only the drug at a therapeutically useful concentration, but also an antioxidant-effective amount of the HCA.


[0037] In a first aspect, t~~T~~here is accordingly provided an orally deliverable pharmaceutical composition comprising (a) a compound of Formula I:



I

where X^3 is chloro or fluoro; and

(1) X^4 is azepan-1-yl, morpholin-4-yl, 1,4-oxazepan-4-yl, pyrrolidin-1-yl, $N(CH_3)_2$, $N(CH_3)(CH(CH_3)_2)$, 7-azabicyclo[2.2.1]heptan-1-yl or 2-oxa-5-azabicyclo[2.2.1] hept-5-yl; and R^0 is




where

X^5 is CH_2, $C(CH_3)_2$ or CH_2CH_2;

X^6 and X^7 are both hydrogen or both methyl; and


X^8 is fluoro, chloro, bromo or iodo; or

(2) X^4 is azepan-1-yl, morpholin-4-yl, pyrrolidin-1-yl, $N(CH_3)(CH(CH_3)_2)$ or 7-azabicyclo[2.2.1]heptan-1-yl; and R^0 is



where X^6, X^7 and X^8 are as above; or

(3) X^4 is morpholin-4-yl or $N(CH_3)_2$; and R^0 is



where X^8 is as above;

or a pharmaceutically acceptable salt, prodrug, salt of a prodrug or metabolite thereof; (b) a pharmaceutically acceptable heavier-chalcogen antioxidant; and (c) a substantially non-aqueous pharmaceutically acceptable carrier that comprises one or more lipids; wherein said compound and the antioxidant are in solution in the carrier.


[0037a] In a second aspect, there is provided a pharmaceutical composition in a form of a liquid solution comprising 5% to 20% by weight ABT-263 free base, 15% to 60% by weight phosphatidylcholine, 7% to 30% by weight medium-chain triglycerides, 7% to 30% by weight medium-chain mono- and diglycerides, 7% to 30% polysorbate 80 surfactant, 0.02% to 0.2% by weight sodium or potassium metabisulfite, 0.003% to 0.01% EDTA or salt thereof, and 0.2% to 0.8% water.

[0037b] In a third aspect, there is provided the use of a composition as defined herein in the manufacture of a medicament for treating a neoplastic disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, by orally administering to a subject having the neoplastic disease a therapeutically effective amount of the composition, wherein the neoplastic disease is selected from the group consisting of cancer, mesothelioma, bladder cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, ovarian cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, bone cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, gastrointestinal (gastric, colorectal and/or duodenal) cancer, chronic lymphocytic leukemia, acute lymphocytic leukemia, esophageal cancer, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, testicular cancer, hepatocellular (hepatic and/or biliary duct) cancer, primary or secondary central nervous system tumor, primary or secondary brain tumor, Hodgkin's disease, chronic or acute

secondary central nervous system tumor, primary or secondary brain tumor, Hodgkin's disease, chronic or acute leukemia, chronic myeloid leukemia, lymphocytic lymphoma, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, multiple myeloma, oral cancer, non-small-cell lung cancer, prostate cancer, small- cell lung cancer, cancer of the kidney and/or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system, primary central nervous system lymphoma, non-Hodgkin's lymphoma, spinal axis tumors, brain stem glioma, pituitary adenoma, adrenocortical cancer, gall bladder cancer, cancer of the spleen, cholangiocarcinoma, fibrosarcoma, neuroblastoma, retinoblastoma and combinations thereof.

[0038] There is further provided an orally deliverable pharmaceutical composition comprising (a) the compound N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl) methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl) amino-3-((trifluoromethyl)sulfonyl)benzenesulfonamide (ABT-263) or a salt, prodrug, salt of a prodrug or metabolite thereof; (b) a pharmaceutically acceptable heavier-chalcogen antioxidant; and (c) a substantially non-aqueous pharmaceutically acceptable carrier that comprises one or more lipids; wherein said compound and the antioxidant are in solution in the carrier. In a still more particular embodiment, the compound is ABT-263 free base or ABT-263 *bis*-hydrochloride salt (ABT-263 *bis*-HCl).

[0039] In some embodiments, the HCA is an antioxidant compound of Formula II:



II

where

n is 0, 1 or 2;

Y^1 is S or Se;

Y^2 is NHR^1, OH or H, where R^1 is alkyl or alkylcarbonyl;

Y^3 is $COOR^2$ or CH_2OH, where R^2 is H or alkyl; and

R^3 is H or alkyl;

where alkyl groups are independently optionally substituted with one of more substituents independently selected from the group consisting of carboxyl, alkylcarbonyl, alkoxycarbonyl, amino and alkylcarbonylamino; a pharmaceutically acceptable salt thereof; or, where Y^1 is S and R^3 is H, an –S–S– dimer thereof or pharmaceutically acceptable salt of such dimer.